Wall Street brokerages expect Henry Schein, Inc. (NASDAQ:HSIC) to announce $0.97 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Henry Schein’s earnings. The lowest EPS estimate is $0.96 and the highest is $0.98. Henry Schein posted earnings per share of $0.94 during the same quarter last year, which would suggest a positive year over year growth rate of 3.2%. The firm is expected to report its next quarterly earnings report on Tuesday, February 20th.
On average, analysts expect that Henry Schein will report full-year earnings of $3.60 per share for the current fiscal year, with EPS estimates ranging from $3.58 to $3.61. For the next year, analysts expect that the company will post earnings of $3.96 per share, with EPS estimates ranging from $3.85 to $4.15. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Henry Schein.
Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.03). Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The company had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the previous year, the firm earned $0.84 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis.
A number of research analysts recently commented on HSIC shares. Morgan Stanley cut Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price target on the stock. in a report on Wednesday, December 6th. Craig Hallum raised Henry Schein from a “hold” rating to a “buy” rating in a report on Tuesday, November 7th. Credit Suisse Group reissued a “neutral” rating and issued a $80.00 price target (down from $87.50) on shares of Henry Schein in a report on Tuesday, November 28th. Zacks Investment Research cut Henry Schein from a “hold” rating to a “sell” rating in a report on Monday, November 13th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 price target on shares of Henry Schein in a report on Wednesday, December 27th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. Henry Schein presently has an average rating of “Hold” and a consensus price target of $84.23.
Henry Schein (NASDAQ:HSIC) opened at $74.84 on Tuesday. Henry Schein has a 12-month low of $65.28 and a 12-month high of $93.50. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.86 and a current ratio of 1.55. The firm has a market capitalization of $11,746.47, a PE ratio of 21.57, a PEG ratio of 1.91 and a beta of 1.00.
Henry Schein announced that its board has initiated a share buyback program on Monday, September 18th that permits the company to repurchase $400.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 6.3% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.
In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of Henry Schein stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $70.76, for a total value of $410,124.96. Following the sale, the director now owns 48,172 shares of the company’s stock, valued at approximately $3,408,650.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.19% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Henry Schein by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 8,086,317 shares of the company’s stock worth $1,479,959,000 after acquiring an additional 236,862 shares during the last quarter. FMR LLC increased its position in shares of Henry Schein by 0.4% during the 2nd quarter. FMR LLC now owns 6,921,367 shares of the company’s stock valued at $1,266,749,000 after purchasing an additional 24,935 shares during the last quarter. BlackRock Inc. increased its position in shares of Henry Schein by 1.8% during the 2nd quarter. BlackRock Inc. now owns 5,696,685 shares of the company’s stock valued at $1,042,607,000 after purchasing an additional 101,406 shares during the last quarter. Alecta Pensionsforsakring Omsesidigt increased its position in shares of Henry Schein by 112.0% during the 3rd quarter. Alecta Pensionsforsakring Omsesidigt now owns 5,313,980 shares of the company’s stock valued at $435,693,000 after purchasing an additional 2,806,990 shares during the last quarter. Finally, Mackenzie Financial Corp increased its position in shares of Henry Schein by 106.0% during the 3rd quarter. Mackenzie Financial Corp now owns 3,938,233 shares of the company’s stock valued at $322,896,000 after purchasing an additional 2,026,867 shares during the last quarter. 91.70% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/16/henry-schein-inc-hsic-expected-to-post-earnings-of-0-97-per-share.html.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Get a free copy of the Zacks research report on Henry Schein (HSIC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.